IPCA Laboratories share news and announcements
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,953.30up ₹49.80 (2.62%)BSE ₹1,951.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.
52-week range of traded prices to 23 Oct 2026
₹1,251.60Low, 24 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹49,556 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 37.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,18,78151.9% delivered
IPCA Laboratories orders, deals and press releases
63 filed, newest first. Page 1 of 2.
Jun 2026
Sep 2025
Aug 2024
Mar 2024
Aug 2023
Jul 2023
May 2023
Apr 2023
24 Apr · Business
Dec 2022
May 2022
Oct 2021
1 Oct · Business
Jun 2021
Apr 2021
30 Apr · Business
Sep 2020
Jan 2020
Apr 2019
Oct 2018
Jan 2018
Aug 2016
May 2016
Feb 2016
Oct 2015
Jul 2015
May 2015
Feb 2015
Nov 2014
Jul 2014
Jun 2014
May 2014
Jan 2014
Oct 2013
Jul 2013
May 2013
Jan 2013
30 Jan · Business
At the meeting of the Board of Directors of the Company held on January 30, 2013, 48,750 fully paid-up equity shares of Rs.2/- each of the Company @ Rs.63/- per equity share have been allotted upon exercise of options by allotees to whom options were granted on November 11, 2008 pursuant to Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS). The equity shares now allotted would rank pari-passu in all respects with the existing paid-up equity share capital of the Company. With this allotment, the paid up equity share capital of the Company is now increased to Rs.25,23,98,218/- divided into 12,61,99,109 fully paid-up equity shares of Rs.2/- each.
Oct 2012
Jul 2012
May 2012
Jan 2012
20 Jan · Business
At the meeting of the Board of Directors held on January 20, 2012; 1,21,250 fully paid-up equity shares of Rs.2/- each of the Company @ Rs.63 per equity share have been allotted upon exercise of options by allotees to whom options were granted on October 29, 2007 and November 11, 2008 pursuant to Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS). Further the Company has informed the Exchange that the equity shares now allotted would rank pari-passu in all respects with the existing paid-up equity share capital of the Company. Also, with this allotment, the paid up equity share capital of the Company is now increased to Rs.25,16,55,310/- divided into 12,58,27,655 fully paid-up equity shares of Rs.2/- each.
Oct 2011
Aug 2011
Jul 2011
Jan 2011
25 Jan · Business
At the meeting of the Board of Directors of the Company held on January 25, 2011, 1,25,000 fully paid-up equity shares of Rs.2/- each of the Company @ Rs.63/- per equity share have been allotted upon exercise of options by allottees to whom options were granted on October 29, 2007 and November 11, 2008 pursuant to Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS). The equity shares now allotted would rank pari-passu in all respects with the existing paid-up equity share capital of the Company. With this allotment, the paid up equity share capital of the Company is now increased to Rs.25,14,12,810/- divided into 12,57,06,405 fully paid-up equity shares of Rs.2/- each.
Oct 2010
22 Oct · Business
At the meeting of the Board of Directors of the Company held on October 22, 2010, 3,53,750 equity shares of Rs. 2/- each of the Company have been allotted @ Rs. 40/- per equity share upon exercise of options by allottees to whom options were granted on September 23, 2006 under Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS). The Equity shares now allotted would rank pari-passu in all respects with the existing paid-up equity share capital of the Company. With this allotment, the paid up equity share capital of the Company is now increased to Rs. 25,11,62,810/- divided into 12,55,81,405 fully paid-up equity shares of Rs. 2/- each.
Jul 2010